GSK’s Melanoma Pill Gets NICE Nod

by Kathy Jones on  September 19, 2014 at 7:57 PM Drug News
RSS Email Print This Page Comment
With GlaxoSmithKline agreeing to provide its melanoma pill Tafinlar at an undisclosed discount price, the National Institute for Health and Care Excellence (NICE) in UK has recommended the drug for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
 GSK’s Melanoma Pill Gets NICE Nod
GSK’s Melanoma Pill Gets NICE Nod

Tafinlar is similar to Roche's Zelboraf and targets a genetic mutation known as BRAF that is linked with melanoma. Results from the BREAK-3 trial revealed that the drug was more effective than dacarbazine in treating patients with the specific kind of melanoma.

NICE's recommendation of the drug has received approval from physicians in the UK. Speaking to the BBC, London's Institute of Cancer Research's Paul Workman said, "Its approval underlines the importance of a new generation of cancer drugs targeted at specific molecular features of [tumors]--drugs which after years of painstaking development are now making their way to patients."

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Skin Cancer Vasectomy Ultra-Violet Radiation Melanoma 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive